Isomerase Therapeutics Ltd.
PrivateLast Round
Corporate Funding
Aug 15, 2016
Est. Valuation
$15.2M
Total Funding Raised
$3.49M
Company Overview
Isomerase Therapeutics Ltd. operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Corporate Funding round in August 2016.
Isomerase Therapeutics Ltd. is a biotechnology company that provides drug discovery, synthetic biology, and bioprocess development services for pharmaceutical, agricultural, and industrial applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Isomerase Therapeutics Ltd. Comparables
Compare Isomerase Therapeutics Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Generare | 84% | |
| Hypha Discovery | 81% | |
| Ingenza Ltd | 78% |
For institutional investors. Book with your work email.
Isomerase Therapeutics Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Aug 15, 2016 | ||||
| Grant | Jun 3, 2016 | ||||
| Strategic | Jan 13, 2016 | ||||
| Grant | Mar 1, 2015 | ||||
| Seed | Apr 4, 2013 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Isomerase Therapeutics Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EPSRC | Grant |
| Innovate UK | Grant |
| Biotechnology and Biological Sciences Research Council | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 90% MoM, reaching 5.4K.
- Sep 16, 2025
Partnering with Regeneron and Abzena on novel payload exploration.
For institutional investors. Book with your work email.
Isomerase Therapeutics Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Isomerase Therapeutics Ltd.'s valuation, stock price, and market status.
Is Isomerase Therapeutics Ltd. a public or private company?
Isomerase Therapeutics Ltd. is a private company.
What is the current stock price of Isomerase Therapeutics Ltd.?
Isomerase Therapeutics Ltd. is a private company, so its shares have no public market price. Caplight tracks Isomerase Therapeutics Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Isomerase Therapeutics Ltd. worth (valuation)?
Isomerase Therapeutics Ltd.'s valuation is estimated at $15.2M based on funding round data.
Can I buy Isomerase Therapeutics Ltd. stock?
Isomerase Therapeutics Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Isomerase Therapeutics Ltd.'s last funding round?
Isomerase Therapeutics Ltd.'s most recent funding round was Corporate Funding on August 15, 2016.
Who are the main investors in Isomerase Therapeutics Ltd.?
Key investors in Isomerase Therapeutics Ltd. include EPSRC, Innovate UK, Biotechnology and Biological Sciences Research Council.
Will Isomerase Therapeutics Ltd. IPO soon?
No public IPO plans have been announced for Isomerase Therapeutics Ltd..
How can I track Isomerase Therapeutics Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Isomerase Therapeutics Ltd.'s shares on secondary markets.